Carotid Stenting and Mechanical Thrombectomy in Patients with Acute Ischemic Stroke and Tandem Occlusions: Antithrombotic Treatment and Functional Outcome

Article Figures & Data

Table 1:

Overall characteristics of the study population

Characteristics
Patient characteristics
Age (mean) (range)	64.6 ± 12.6 (29–86)
Male sex (No./No.) (%)	69/95 (72.6%)
Left-hemisphere stroke (No./No.) (%)	56/95 (58.9%)
Baseline NIHSS (mean) (range)	16.8 ± 5.5; 2–32
Baseline ASPECTS (median) (range)	8; 2–10
Tobacco (No./No.) (%)	35/95 (36.8%)
Diabetes mellitus (No./No.) (%)	7/95 (7.4%)
Dyslipidemia (No./No.) (%)	16/95 (16.8%)
Atrial fibrillation at admission (No./No.) (%)	10/95 (10.5%)
Prestroke antiplatelet therapy (No./No.) (%)	21/95 (22.1%)
Procedural and postprocedural characteristics
Onset-to-groin time (mean) (range)	284.5 ± 156.4; 70–980 min
Onset-to-recanalization (mean) (range)	376.7 ± 168.3; 110–1075 min
Procedural time (mean) (range)	90.6 ± 58.2; 9–315 min
No. of MT attempts (mean) (range)	2.57 ± 1.7; 1–10
Successful recanalization mTICI ≥2b (No./No.) (%)	58/95 (61.1%)
Intravenous thrombolysis (No./No.) (%)	45/95 (47.4%)
Single-layer carotid stent (No./No.) (%)	87/95 (91.6%)
Dual-layer carotid stent (No./No.) (%)	8/95 (8.4%)
Intraprocedural heparin (No./No.) (%)	40/95 (42.1%)
Intraprocedural single-antiplatelet therapy (No./No.) (%)	46/79 (58.2%)
Intraprocedural dual-antiplatelet therapy (No./No.) (%)	10/43 (23.3%)
Postprocedural single-antiplatelet therapy (No./No.) (%)	25/54 (46.3%)
Postprocedural dual-antiplatelet therapy (No./No.) (%)	30/60 (50%)
Symptomatic ICH	26/94 (27.7%)

Table 2:

Multivariate analysis of factors influencing symptomatic ICH and functional independence

Factors	Mean	95% CI	P Value
Influencing symptomatic ICH
Intraprocedural heparin ≥3000 IU	3547 ± 588 IU	2377–4718	.01
ASPECTS ≤7	6.6 ± 0.4	5.8–7.4	.001
MT attempts ≥3	3.3 ± 0.3	2.6–4.1	.002
Influencing functional independence (mRS ≤2)
ASPECTS ≥8	8.4 ± 0.4	7.9–9.2	.001
MT attempts ≤2	1.9 ± 0.3	1.3–2.5	.004